CellPro's CEPRATE SC Stem Cell Concentration System is beingtested in two clinical trials (in addition to a series of other trialsalready begun) in France. The trials are intended to determinethe safety and efficacy of the device in concentrating stem cellsfrom autologous peripheral blood, the capacity of the stem cellsto accelerate hematological recovery following myeloablativetherapy, and the device's efficacy in depleting tumor cells fromperipheral blood.

In one of the French trials, being conducted at the InstitutGustave Roussey in Paris, multiple myeloma patients are beingtreated with chemotherapy and total body irradiation. In theother, under way at the Hopital Saint Louis in Paris, patientswith advanced metastatic breast cancer or with relapsedmalignant lymphoma are being treated with chemotherapy.

Cellpro's device is currently being tested in about 20 trials,including two other Phase I/II trials in France; two Phase I/IItrials in Germany, and about 14 trials in the U.S. A Phase IIItrial was recently completed in the U.S. and Bothell, Wash.-based Cellpro (NASDAQ:CPRO) plans to file a premarketapproval application (PMA) with FDA in December.

(c) 1997 American Health Consultants. All rights reserved.